Jeiroodi Naghmeh, Bagherpour Mahshid, Zare Razieh, Torabi Ardakani Shima, Andisheh Tadbir Azadeh
Department of Oral and Maxillofacial Pathology, School of Dentistry, Shiraz University of Medical Sciences, SHIRAZ, IRAN.
Turk Patoloji Derg. 2018;34(2):158-164. doi: 10.5146/tjpath.2017.01421.
Midkine is a heparin-binding growth factor whose expression is increased in most tumors, namely ameloblastomas. This study aimed to compare Midkine expression in different odontogenic lesions.
This analytical cross-sectional study was performed on 52 definitely diagnosed odontogenic lesions including 15 dentigerous cysts, 13 odontogenic keratocysts, and 17 unicystic and 5 multicystic ameloblastomas archived from 1997 to 2015. Midkine expression was examined in tissue samples through immunohistochemistry. The nonparametric Kruskal-Wallis and Mann-Whitney tests were run as appropriate (P < 0.05).
The frequency of Midkine expression was < 20% in 7.7%, 20-50% in 25%, and > 50 % in 67.3% of the samples, indicating significant differences among the groups (P = 0.002). Moreover, the expression intensity was strong in 63.5%, moderate in 23.1%, and weak in 13.5% of odontogenic lesion samples (P = 0.071). The total staining score was weak in 3.8%, moderate in 48.1%, and strong in 48.1% of the cells, displaying significant differences between the study groups in this regard (P = 0.043).
Midkine can be considered as both a differentiating factor and a molecular-targeted therapy in odontogenic lesions. Yet, further studies are required to approve the role of this cytokine in different biological and pathological stages of the tumors.
中期因子是一种肝素结合生长因子,其在大多数肿瘤中表达增加,成釉细胞瘤也不例外。本研究旨在比较中期因子在不同牙源性病变中的表达情况。
本分析性横断面研究对52例明确诊断的牙源性病变进行了研究,这些病变包括1997年至2015年存档的15例含牙囊肿、13例牙源性角化囊肿、17例单囊和成釉细胞瘤以及5例多囊和成釉细胞瘤。通过免疫组织化学检测组织样本中的中期因子表达。根据情况进行非参数Kruskal-Wallis检验和Mann-Whitney检验(P<0.05)。
在7.7%的样本中,中期因子表达频率<20%;在25%的样本中,表达频率为20%-50%;在67.3%的样本中,表达频率>50%,表明各组之间存在显著差异(P=0.002)。此外,在牙源性病变样本中,63.5%的样本表达强度强,23.1%的样本表达强度中等,13.5%的样本表达强度弱(P=0.071)。在3.8%的细胞中,总染色评分为弱,48.1%的细胞评分为中等,48.1%的细胞评分为强,在这方面研究组之间存在显著差异(P=0.043)。
中期因子可被视为牙源性病变中的一种分化因子和分子靶向治疗手段。然而,需要进一步研究来证实这种细胞因子在肿瘤不同生物学和病理阶段中的作用。